BR9610331A - Composições farmacêuticas para distribuição nasal de compostos úteis para o tratamento de osteoporose - Google Patents
Composições farmacêuticas para distribuição nasal de compostos úteis para o tratamento de osteoporoseInfo
- Publication number
- BR9610331A BR9610331A BR9610331-0A BR9610331A BR9610331A BR 9610331 A BR9610331 A BR 9610331A BR 9610331 A BR9610331 A BR 9610331A BR 9610331 A BR9610331 A BR 9610331A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical compositions
- compounds useful
- nasal delivery
- treating osteoporosis
- osteoporosis
- Prior art date
Links
- 208000001132 Osteoporosis Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 101150071808 PTHLH gene Proteins 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 239000003613 bile acid Substances 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"COMPOSIçõES FARMACêUTICAS PARA DISTRIBUIçãO NASAL DE COMPOSTOS úTEIS PARA O TRATAMENTO DE OSTEOPOROSE". é fornecida uma composição farmacêutica para a distribuição nasal de compostos úteis para tratamento de osteoporose, compreendendo uma quantidade eficaz de um análogo truncado fisiologicamente ativo de PTH ou PTHrp, ou sal do mesmo, no qual resíduos de aminoácidos (22-31) formam uma <244>-hélice anfipática, os referidos resíduos (22-31) selecionados de (SEQ ID N^ os^: 85, 86, 26, 27, 28, 29 e 30); um intensificador de absorção selecionado do grupo que consiste de dimetil-<225>-ciclodextrina e os tensoativos de ácido de bile; e água.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/521,097 US5977070A (en) | 1992-07-14 | 1995-08-29 | Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis |
PCT/US1996/013769 WO1997007815A2 (en) | 1995-08-29 | 1996-08-22 | Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9610331A true BR9610331A (pt) | 2005-05-10 |
Family
ID=24075345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9610331-0A BR9610331A (pt) | 1995-08-29 | 1996-08-22 | Composições farmacêuticas para distribuição nasal de compostos úteis para o tratamento de osteoporose |
Country Status (9)
Country | Link |
---|---|
US (1) | US5977070A (pt) |
EP (1) | EP0858344A2 (pt) |
JP (1) | JPH11511462A (pt) |
CN (1) | CN1193915A (pt) |
AU (1) | AU6958996A (pt) |
BR (1) | BR9610331A (pt) |
CA (1) | CA2230929A1 (pt) |
TR (1) | TR199800335T1 (pt) |
WO (1) | WO1997007815A2 (pt) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002064091A2 (en) * | 2001-02-13 | 2002-08-22 | Palatin Technologies, Inc. | Melanocortin metallopeptides for treatment of sexual dysfunction |
US6147186A (en) | 1996-07-31 | 2000-11-14 | The General Hospital Corporation | Parathyroid hormone-related peptide analogs |
EP0976070A1 (en) * | 1997-04-17 | 2000-02-02 | Glaxo Group Limited | Statistical deconvoluting of mixtures |
BR9812068A (pt) * | 1997-09-09 | 2000-09-26 | Hoffmann La Roche | Processo para a cicatrização óssea e restauração de fraturas e utilização de um análogo de polipeptìdeo de peptìdeo (pthrp) relacionado com hormÈnios de paratireóide e seus sais |
US20070072828A1 (en) * | 1998-07-24 | 2007-03-29 | Yoo Seo H | Bile preparations for colorectal disorders |
US7772220B2 (en) * | 2004-10-15 | 2010-08-10 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
US7303768B2 (en) * | 1998-07-24 | 2007-12-04 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
US20050158408A1 (en) * | 1998-07-24 | 2005-07-21 | Yoo Seo H. | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
WO2000019823A1 (en) * | 1998-10-07 | 2000-04-13 | The Board Of Trustees Of The University Of Arkansas | Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof |
JP4486256B2 (ja) * | 1998-10-22 | 2010-06-23 | ザ・ジェネラル・ホスピタル・コーポレイション | 副甲状腺ホルモン(PTH)および副甲状腺ホルモン関連ペプチド(PTHrP)の生物活性ペプチドおよびペプチド誘導体 |
EP1147133B1 (en) * | 1998-12-31 | 2008-08-06 | The General Hospital Corporation | Peptides consisting of two PTH functional domains fused by a linker molecule, and derivatives thereof |
US7057012B1 (en) | 1998-12-31 | 2006-06-06 | The General Hospital Corporation | PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
US7176279B2 (en) * | 2000-06-28 | 2007-02-13 | Palatin Technologies, Inc. | Cyclic peptide compositions and methods for treatment of sexual dysfunction |
US6579968B1 (en) * | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
WO2001023521A2 (en) * | 1999-09-29 | 2001-04-05 | The General Hospital Corporation | Polypeptide derivatives of parathyroid hormone (pth) |
CN100558407C (zh) * | 2000-02-04 | 2009-11-11 | 柳署弘 | 制备含有胆汁酸的澄清水溶液剂型 |
IL153678A0 (en) * | 2000-06-30 | 2003-07-06 | Suntory Ltd | A pharmaceutical component comprising a human parathyroid hormone |
US7345144B2 (en) * | 2001-07-11 | 2008-03-18 | Palatin Technologies, Inc. | Cyclic peptides for treatment of cachexia |
US7342089B2 (en) * | 2001-07-11 | 2008-03-11 | Palatin Technologies, Inc. | Cyclic peptides for treatment for cachexia |
KR100491737B1 (ko) * | 2001-07-20 | 2005-05-27 | 주식회사 한국아이템개발 | 공기 정화 기능의 모기 퇴치기 |
AU2002339843B2 (en) | 2001-07-23 | 2007-12-06 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (PTH) analogs |
US7015195B2 (en) * | 2002-01-10 | 2006-03-21 | Osteotrophin, Llc | Treatment of bone disorders with skeletal anabolic drugs |
EP1476153A2 (en) | 2002-02-08 | 2004-11-17 | F. Hoffmann-La Roche Ag | Method of treating and preventing bone loss |
US7906480B2 (en) * | 2002-05-23 | 2011-03-15 | Michael Holick | Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy |
WO2004005324A2 (en) * | 2002-07-09 | 2004-01-15 | Palatin Technologies, Inc. | Peptide composition for treatment of sexual dysfunction |
US7029657B2 (en) * | 2002-08-02 | 2006-04-18 | Balance Pharmaceuticals, Inc. | Nasal spray steroid formulation and method |
US6960337B2 (en) * | 2002-08-02 | 2005-11-01 | Balance Pharmaceuticals, Inc. | Methods and compositions for treating benign gynecological disorders |
US6958142B2 (en) * | 2002-08-02 | 2005-10-25 | Balance Pharmaceuticals, Inc. | Nasal spray formulation and method |
WO2004093902A1 (en) * | 2003-03-19 | 2004-11-04 | The General Hospital Corporation | CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH α-HELIX STABILIZERS |
ES2425221T3 (es) | 2003-05-30 | 2013-10-14 | Amylin Pharmaceuticals, Llc | Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas |
US7145125B2 (en) | 2003-06-23 | 2006-12-05 | Advanced Optical Technologies, Llc | Integrating chamber cone light using LED sources |
WO2005009358A2 (en) | 2003-07-17 | 2005-02-03 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (pth) analogs |
BRPI0418386A (pt) | 2003-12-31 | 2007-05-22 | Cydex Inc | formulação inalante contendo éter sulfoalquìlico gama-ciclodextrina e corticosteróide |
US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US6974187B2 (en) * | 2004-01-28 | 2005-12-13 | Tachi-S Co., Ltd. | Vehicle seat structure |
EP3520779B1 (en) * | 2004-04-23 | 2021-12-22 | CyDex Pharmaceuticals, Inc. | Dpi formulation containing sulfoalkyl ether cyclodextrin |
MXPA06012980A (es) * | 2004-05-10 | 2007-06-12 | Nastech Pharm Co | Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea. |
US20060052305A1 (en) * | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | Method of treating osteoporosis using intranasal parathyroid hormone |
US20060052306A1 (en) * | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | GRAS composition for enhanced mucosal delivery of parathyroid hormone |
US20060127320A1 (en) * | 2004-05-10 | 2006-06-15 | Nastech Pharmaceutical Company Inc. | Method of delivering parathyroid hormone to a human |
US20090069226A1 (en) * | 2004-05-28 | 2009-03-12 | Amylin Pharmaceuticals, Inc. | Transmucosal delivery of peptides and proteins |
AU2005279961B2 (en) * | 2004-08-30 | 2010-05-13 | Seo Hong Yoo | Neuroprotective effect of solubilized UDCA in focal ischemic model |
WO2006044771A2 (en) * | 2004-10-15 | 2006-04-27 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
JP2008518935A (ja) * | 2004-11-01 | 2008-06-05 | セオ ホン ユー | 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物 |
US7754691B1 (en) | 2005-07-07 | 2010-07-13 | Palatin Technologies, Inc. | Linear melanocortin receptor-specific peptides for cachexia |
US20070173447A1 (en) * | 2005-10-25 | 2007-07-26 | Nastech Pharmaceutical Company Inc. | Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent |
US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
US8247530B2 (en) * | 2005-11-08 | 2012-08-21 | Palatin Technologies, Inc. | N-alkylated cyclic peptide melanocortin agonists |
EP1945245A2 (en) * | 2005-11-10 | 2008-07-23 | The Board of Control of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
US20080051332A1 (en) * | 2005-11-18 | 2008-02-28 | Nastech Pharmaceutical Company Inc. | Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone |
US20070160542A1 (en) * | 2005-12-20 | 2007-07-12 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
US20070249572A1 (en) * | 2005-12-20 | 2007-10-25 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
US20070185066A1 (en) * | 2005-12-20 | 2007-08-09 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
US20070197486A1 (en) * | 2005-12-20 | 2007-08-23 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids |
EP1988880A2 (en) * | 2006-02-15 | 2008-11-12 | Tika Läkemedel AB | Stable mixture of corticosteroids |
WO2007115182A2 (en) * | 2006-03-30 | 2007-10-11 | Palatin Technologies, Inc. | Linear natriuretic peptide constructs |
US8580746B2 (en) * | 2006-03-30 | 2013-11-12 | Palatin Technologies, Inc. | Amide linkage cyclic natriuretic peptide constructs |
WO2007115175A2 (en) * | 2006-03-30 | 2007-10-11 | Palatin Technologies, Inc. | Cyclic natriuretic peptide constructs |
US8685485B2 (en) * | 2006-05-19 | 2014-04-01 | Solae, Llc | Protein composition and its use in restructured meat and food products |
EP2054077A4 (en) * | 2006-08-04 | 2010-10-13 | Gen Hospital Corp | POLYPEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) |
USRE49444E1 (en) | 2006-10-03 | 2023-03-07 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
US7803770B2 (en) * | 2006-10-03 | 2010-09-28 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
ES2739459T3 (es) * | 2006-10-03 | 2020-01-31 | Radius Health Inc | Una composición estable que comprende una proteína anabólica ósea, es decir un análogo de PTHrP y usos de la misma |
EP1961765A1 (en) * | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
US8568737B2 (en) | 2007-08-01 | 2013-10-29 | The General Hospital Corporation | Screening methods using G-protein coupled receptors and related compositions |
WO2010065802A2 (en) | 2008-12-04 | 2010-06-10 | Palatin Technologies, Inc. | Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds |
WO2010065801A1 (en) | 2008-12-04 | 2010-06-10 | Palatin Technologies, Inc. | Amine substituted piperazine melanocortin receptor-specific compounds |
WO2010065799A2 (en) | 2008-12-04 | 2010-06-10 | Palatin Technologies, Inc. | Amine substituted piperidine melanocortin receptor-specific compounds |
CA2761607C (en) | 2009-06-08 | 2018-09-04 | Yi-Qun Shi | Melanocortin receptor-specific peptides |
AU2009356227A1 (en) | 2009-12-07 | 2012-06-21 | Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
KR101900078B1 (ko) | 2010-05-13 | 2018-09-18 | 더 제너럴 하스피탈 코포레이션 | 부갑상선 호르몬 아날로그 및 그의 용도 |
US9534018B2 (en) | 2012-03-13 | 2017-01-03 | Tensive Controls Inc. | Melanocortin analogs having enhanced activity and transport |
WO2014021694A1 (ko) * | 2012-08-03 | 2014-02-06 | 서울대학교 산학협력단 | 골 관련 질환 예방 및 치료를 위한 조성물 |
WO2016044683A1 (en) | 2014-09-19 | 2016-03-24 | Tensive Controls, Inc. | Anti-microbial peptides |
RU2745678C2 (ru) | 2015-04-29 | 2021-03-30 | Радиус Фармасьютикалз, Инк. | Способы лечения рака |
KR102322802B1 (ko) | 2017-01-05 | 2021-11-04 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
US10996208B2 (en) | 2017-04-28 | 2021-05-04 | Radius Health, Inc. | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
AU2019297421A1 (en) | 2018-07-04 | 2021-01-28 | Radius Pharmaceuticals, Inc. | Polymorphic forms of RAD 1901-2HCL |
AU2020204925A1 (en) | 2019-01-03 | 2021-07-22 | Cyclarity Therapeutics, Inc. | Cyclodextrin dimers, compositions thereof, and uses thereof |
CN114057863B (zh) * | 2020-08-06 | 2023-10-20 | 珠海联邦制药股份有限公司 | 一种甲状旁腺激素相关肽类似物及其应用 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4086196A (en) * | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
US4423037A (en) * | 1982-05-13 | 1983-12-27 | The General Hospital Corporation | Inhibitors of peptide hormone action |
US5116817A (en) * | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
US4738921A (en) * | 1984-09-27 | 1988-04-19 | Eli Lilly And Company | Derivative of the tryptophan operon for expression of fused gene products |
EP0212532A1 (en) * | 1985-08-12 | 1987-03-04 | Syntex (U.S.A.) Inc. | Method for producing fusion proteins |
DE3751997T2 (de) * | 1986-07-18 | 1997-07-10 | Univ Melbourne | Aktives protein in humoraler hyperkalzemia, durch bösartigkeit verursacht |
EP0260350B1 (en) * | 1986-09-05 | 1992-02-12 | Cetus Oncology Corporation | Oxidation-resistant interferon-beta muteins and their production; formulations containing such muteins |
US5010010A (en) * | 1986-10-22 | 1991-04-23 | Selmer-Sande, A.S. | Production of human parathyroid hormone from microorganisms |
US4833125A (en) * | 1986-12-05 | 1989-05-23 | The General Hospital Corporation | Method of increasing bone mass |
US4835255A (en) * | 1987-03-26 | 1989-05-30 | Yale University | T-cell membrane protein |
EP0293160A3 (en) * | 1987-05-26 | 1990-05-09 | Merck & Co. Inc. | Parathyroid hormone antagonists with enhanced metabolic properties |
EP0293158A3 (en) * | 1987-05-26 | 1990-05-09 | Merck & Co. Inc. | Parathyroid hormone antagonists |
US5001223A (en) * | 1987-05-26 | 1991-03-19 | Merck & Co., Inc. | Parathyroid hormone antagonists with enhanced metabolic properties |
US4771124A (en) * | 1987-05-26 | 1988-09-13 | Merck & Co., Inc. | Parathyroid hormone antagonists with simplified synthetic methodology |
DE3725319A1 (de) * | 1987-07-30 | 1989-02-09 | Biotechnolog Forschung Gmbh | Pth-modifikationen und therapeutische zusammensetzungen, die sie enthalten und daraus bestehen |
DE3725320A1 (de) * | 1987-07-30 | 1989-02-09 | Biotechnolog Forschung Gmbh | Expressionsvektoren und verfahren unter deren verwendung zur gewinnung von cro/ss-galaktosidase/pth-fusionsproteinen und von pth |
GB2212062B (en) * | 1987-11-13 | 1991-07-17 | Isf Spa | Pharmaceutical compositions containing a calcitonin and a glycyrrhizinate ab- sorption enhancer |
US4861756A (en) * | 1988-03-08 | 1989-08-29 | Merrell Dow Pharmaceuticals Inc. | Synthetic pulmonary surfactant |
US4968669A (en) * | 1988-05-09 | 1990-11-06 | Merck & Co., Inc. | Parathyroid hormone antagonists |
EP0341963A3 (en) * | 1988-05-09 | 1991-07-24 | Merck & Co. Inc. | Parathyroid hormone antagonists |
NL8801670A (nl) * | 1988-07-01 | 1990-02-01 | Walter Adrianus Josephus Johan | Farmaceutisch preparaat. |
EP0470974B1 (en) * | 1989-04-10 | 2000-01-26 | Helix BioMedix, Inc. | Lytic peptides, use for growth, infection and cancer |
US5171670A (en) * | 1989-05-12 | 1992-12-15 | The General Hospital Corporation | Recombinant dna method for production of parathyroid hormone |
CA2040264A1 (en) * | 1990-04-12 | 1991-10-13 | Tatsuhiko Kanmera | Parathyroid hormone antagonists |
US5087562A (en) * | 1990-04-25 | 1992-02-11 | Merck & Co., Inc. | Humoral hypercalcemic factor antagonists with modification at position 13 . . . |
US5093233A (en) * | 1990-04-25 | 1992-03-03 | Merck & Co., Inc. | Antagonists with position 13 modification |
WO1992000753A1 (en) * | 1990-07-13 | 1992-01-23 | The Regents Of The University Of California | PARATHYROID HORMONE ANALOGUES MODIFIED AT POSITIONS 3, 6 or 9 |
NL9001681A (nl) * | 1990-07-24 | 1992-02-17 | Rijksuniversiteit | Transmucosale geneesmiddelpreparaten en transmucosale toediening. |
US5149779A (en) * | 1990-07-26 | 1992-09-22 | Merck & Co., Inc. | Humoral hypercalcemic factor antagonists |
GB9020544D0 (en) * | 1990-09-20 | 1990-10-31 | Sandoz Ltd | Improvements in or relating to organic compounds |
JPH0532696A (ja) * | 1990-09-28 | 1993-02-09 | Takeda Chem Ind Ltd | 副甲状腺ホルモン誘導体 |
DE4039656A1 (de) * | 1990-12-12 | 1992-06-17 | Bissendorf Peptide Gmbh | Arzneimittel, enthaltend das humane parathormon-fragment (1-37) in der form des amids oder ethylamids als aktiven wirkstoff |
WO1992011286A1 (en) * | 1990-12-21 | 1992-07-09 | Allelix Biopharmaceuticals Inc. | Oxidation resistant variants of parathyroid hormone |
US5317010A (en) * | 1991-10-10 | 1994-05-31 | Peter K. T. Pang | Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment |
US5434246A (en) * | 1992-03-19 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Parathyroid hormone derivatives |
US5382658A (en) * | 1992-04-03 | 1995-01-17 | Allelix Biopharmaceuticals Inc. | Stability-enhanced variants of parathyroid hormone |
US5589452A (en) * | 1992-07-14 | 1996-12-31 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
US5821225A (en) * | 1992-07-14 | 1998-10-13 | Syntex (U.S.A.) Inc. | Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp |
CN1070500C (zh) * | 1993-07-13 | 2001-09-05 | 森德克斯(美国)股份有限公司 | 甲状旁腺激素类似物和甲状旁腺激素相关肽:合成和治疗骨质疏松症的用途 |
-
1995
- 1995-08-29 US US08/521,097 patent/US5977070A/en not_active Expired - Fee Related
-
1996
- 1996-08-22 JP JP9510521A patent/JPH11511462A/ja active Pending
- 1996-08-22 WO PCT/US1996/013769 patent/WO1997007815A2/en not_active Application Discontinuation
- 1996-08-22 TR TR1998/00335T patent/TR199800335T1/xx unknown
- 1996-08-22 BR BR9610331-0A patent/BR9610331A/pt unknown
- 1996-08-22 EP EP96930607A patent/EP0858344A2/en not_active Ceased
- 1996-08-22 AU AU69589/96A patent/AU6958996A/en not_active Abandoned
- 1996-08-22 CN CN96196522A patent/CN1193915A/zh active Pending
- 1996-08-22 CA CA002230929A patent/CA2230929A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX9801630A (es) | 1998-08-30 |
WO1997007815A2 (en) | 1997-03-06 |
AU6958996A (en) | 1997-03-19 |
US5977070A (en) | 1999-11-02 |
EP0858344A2 (en) | 1998-08-19 |
JPH11511462A (ja) | 1999-10-05 |
CN1193915A (zh) | 1998-09-23 |
TR199800335T1 (xx) | 1998-05-21 |
CA2230929A1 (en) | 1997-03-06 |
WO1997007815A3 (en) | 1997-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9610331A (pt) | Composições farmacêuticas para distribuição nasal de compostos úteis para o tratamento de osteoporose | |
RU2224539C2 (ru) | Заживление переломов с помощью аналогов пептида, подобного паратироидному гормону (ртнrр) | |
BR9808786A (pt) | Composto peptìdio cìclico ou um seu sal ou pró-medicamento farmaceuticamente aceitáveis, composição farmacêutica, e, processos para tratar doenças associadas com a regulagem do cálcio em um paciente e para tratar a osteopenia ou a osteoporose em um mamìfero hospedeiro | |
AU703137B2 (en) | Use of tasteless, hydrolyzed collagen and agent containing the same | |
EA200001125A1 (ru) | Гелеобразные фармацевтические композиции | |
GEP20032925B (en) | Benzothiepines Having Activity As Inhibitors of Ileal Bile Acid Transport and Taurocholate Uptake | |
ATE311196T1 (de) | Zusammensetzungen geeignet zur kontrollierten freisetzung des hormons gnrh und dessen analoga | |
BR9810911A (pt) | Composto, e, processo para tratar câncer em um mamìfero | |
RU93054017A (ru) | Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза | |
BR9809492A (pt) | Composição farmacêutica aquosa injetável, e, processo para a preparação da mesma | |
DE69838647D1 (de) | Behandlung von fettleibigkeit | |
MX9300586A (es) | Nuevos fragmentos de hormona paratiroidea proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
KR970061249A (ko) | 골다공증을 치료 또는 방지하기 위한 조성물 | |
BR9612355A (pt) | Agentes de ligação com os receptores de ácido hialurÈnico e o uso destes. | |
ES2194767T3 (es) | Mezcla para tratar material de desecho. | |
ATE194076T1 (de) | Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen | |
KR970705397A (ko) | 골다공증 치료를 위한 에스트로젠 화합물 및 부갑상선 호르몬(estrogens and parathyroid hormone for treating osteoporosis) | |
Selye et al. | Protection by restraint against parathyroid hormone intoxication | |
KR960701642A (ko) | 골다공증의 치료를 위한 방법 및 조성물(method and composition for treatment of osteoporosis) | |
PT100075A (pt) | Acidos aril- ou arilalquil-acil-amino-alquil-hidroxidifosfonicos, um processo para a sua preparacao e sua utilizacao na terapia de perturbacoes do tecido osteoarticular e conjuntivo | |
KR960701644A (ko) | 골다공증의 치료를 위한 방법 및 조성물(method and composition for treatment of osteoporosis) | |
DE69915852D1 (de) | Lhrh-analoga zur behandlung der osteoporose | |
EP0817643A4 (en) | COMPOUNDS AND COMPOSITIONS FOR PROVIDING ACTIVE AGENTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8O E 9A ANUIDADES. |